Navigation Links
Mylan Launches Thiamine Hydrochloride Injection
Date:6/28/2012

PITTSBURGH, June 28, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Mylan Institutional business has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for preservative-free Thiamine Hydrochloride Injection, 100 mg/mL, packaged in 200 mg/2 mL multiple-dose vials. This product is indicated for the treatment of thiamine deficiency.

Thiamine Hydrochloride Injection, 100 mg/mL, had U.S. sales of approximately $18.6 million for the 12 months ending March 31, 2012, according to IMS Health. Mylan is shipping this product, presented in 25-vial packs, immediately.

Currently, Mylan has 169 ANDAs pending FDA approval representing $83.9 billion in annual sales, according to IMS Health. Thirty-seven of these pending ANDAs are potential first-to-file opportunities, representing $25.6 billion in annual brand sales, for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com 

 

 

 


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
3. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
4. Mylan Launches Generic Lipitor® in Five European Countries
5. Mylan Launches Generic Version of Plavix® Tablets
6. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
11. Mylan Launches Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 /PRNewswire/ ... University of Alberta in Edmonton, Canada ... partner journal, Schizophrenia 1 , demonstrating that AI ... schizophrenia with 74% accuracy. This retrospective analysis also ... symptoms in schizophrenia patients with significant correlation, based ...
(Date:7/21/2017)... 21, 2017  Endo International plc (NASDAQ: ... review of its manufacturing network, the Company will be ... in Huntsville, Alabama . The closure ... the next 12 to 18 months. The ... volumes of commoditized products and these restructuring actions are ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... , ... “Now Hiring!” is a popular phrase at Home Delivery Incontinent ... sales for over 30 consecutive years and now plans to hire more than 100 ... excitement and growth at HDIS, following the company’s acquisition by Fortune 1000 company Domtar. ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... the launch of their partnership to provide the Pharmacist eCare Plan ... platform in the country with the ability to develop the Pharmacist eCare Plan, ...
(Date:7/25/2017)... Spring Arbor, Mich. (PRWEB) , ... July 25, ... ... director of special education programs at Spring Arbor University recently co-authored and published ... of Self-Determination in Adolescents with Neonatal Brachial Plexus Palsy. Both the article and ...
(Date:7/25/2017)... ... 25, 2017 , ... Facing medical needs with a newborn boy this spring, ... a new benefit for employees that is uncommon in American business: 12 weeks of ... me and other employees as new parents. It keeps our family life more stable. ...
(Date:7/24/2017)... ... 24, 2017 , ... Engineers at the University of Maryland have invented an ... of electrical energy that the body uses. , In ordinary batteries the electrical ... electrons out of the battery is generated by moving positive ions from one end ...
Breaking Medicine News(10 mins):